CRISPR Therapeutics (CRSP) said Thursday that new phase 1 clinical data for its treatment CTX310 continues to demonstrate dose-dependent reductions in triglycerides and low-density lipoprotein, which are recognized risk factors for atherosclerotic heart disease.
The data showed peak reduction of up to 82% in triglycerides and up to 86% in low-density lipoprotein, with a well-tolerated safety profile, the company said.
CRISPR said it expects to present complete phase 1 data of CTX310, which targets the ANGPTL3 gene, at a medical meeting in H2.
The company said it also expects an update for its phase 1 trial of CTX320 in H1 2026. The investigational treatment targets the LPA gene in patients with elevated lipoprotein, a genetically determined risk factor associated with increased incidence of major adverse cardiovascular events.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。